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Abstract Calcitonin gene-related peptide (CGRP) is
known to increase during acute attack of migraine and
tension type headache (TTH). However, its concentration
during inter-ictal period is not known. This may help us to
understand the pathophysiology of these headaches. The
objectives of this study are to find out the concentration of
CGRP in plasma during inter-ictal period among migrai-
neurs and TTH and to compare it with control group
through cross-sectional study from headache clinic of a
tertiary centre. Study sample comprised of three groups:
migraineurs, TTH subjects as well as a healthy control
group. Fifty subjects in each group were included after
screening for the respective inclusion criteria and exclusion
criteria. None of the subjects was blood relatives of other
subject. Their venous blood was drawn and plasma was
separated to be kept at -70C. CGRP was analysed with
commercially available ELISA kit. Data were analysed
with the help of SPSS V 11.0 for Windows. Chi-square,
independent sample t test and one-way ANOVA with post
hoc Tukey and univariate regression were performed.
Plasma CGRP concentration was not different among three
diagnostic groups (F = 0.78; P = 0.49). Similarly, plasma
CGRP concentration was not different among episodic
TTH and chronic TTH groups (t = 0.32; P = 0.97) and
comparison of episodic and chronic migraine groups also
revealed similar results in this study (1.14 vs. 0.94 ng/ml;
P = 0.23). The presence of aura did not affect the inter-
ictal CGRP levels among migraineurs (F = 0.16;
P = 0.85). In conclusion, this study suggests that migraine
and TTH could be episodic disorders and subjects have
comparable CGRP levels during inter-ictal period.
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Introduction
Calcitonin gene-related peptide (CGRP) is located in the
trigeminal nuclei and it is released during headache in the
circulation [1, 2]. A number of studies had considered
CGRP to be central in the pathogenesis of migraine as well
as tension type headache (TTH) [3–6].
Its role in migraine is suggested by five kind of evi-
dences: (a) higher level of plasma CGRP during
spontaneous headache as compared to controls [7]; (b)
increment in plasma CGRP level during experimental
migraine attacks [8]; (c) lowering of plasma CGRP level
with anti-migraine drugs [9]; (d) reports describing the
relief in migraine with CGRP antagonists [10, 11]; and (e)
initiation of migraine among migraineurs after human
alpha CGRP infusion [12]. Some studies tried to correlate
the clinical symptoms of migraine with plasma CGRP level
and found that its level correlates with the intensity and
duration of headache and touches the base-line after an
attack is over [7, 13]. Thus, these studies suggest that
migraine is essentially an episodic disorder. However,
electrophysiological data suggest that brain remains hyper-
excitable even in between the migraine episodes and it
predisposes a person to have migraine attacks further [14].
Based on this assumption, some studies assessed plasma
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CGRP level in between episodes and came out with the
conflicting reports [6, 13, 15–17].
Similar studies in chronic TTH subjects failed to find
increase in plasma CGRP levels and only one study sug-
gested that TTH subjects with pulsating pain harbour
higher CGRP concentration in plasma during pain [18, 19].
To our knowledge, such studies were never attempted in
episodic TTH subjects.
In addition, previous studies included only two groups,
i.e., either of the headache and a control group. At least, to
best of our knowledge, vis-a`-vis comparison of plasma
CGRP level between migraine and TTH subjects is not
available. As a result, its role in both the conditions cannot
be compared directly. Secondly, many of these studies are
silent regarding the confounding factors that may affect
CGRP levels, e.g., obesity, intake of fatty meal, exercise,
etc., in relation to the blood sample collection [20–22].
CGRP antagonists are considered useful for acute attack
of migraine only and literature is not available regarding
their use in TTH [5]. However, if the CGRP levels remain
elevated outside the headache in migraineurs as well as
TTH sufferers, it is possible that these drugs may be used
for the prophylactic therapy also.
Hence, the present study was planned to assess the
plasma level of CGRP outside headache episode in
migraineurs as well as TTH subjects and control group
after exclusion of all possible confounding factors.
Methods
Fifty consecutive subjects suffering from migraine, 50
consecutive subjects of TTH and 50 consecutive controls
meeting inclusion criteria were recruited from the headache
clinic of a teaching hospital after screening for the exclu-
sion criteria. The study was approved by the institutional
ethics committee and informed consent was obtained from
all the study subjects. Migraine and TTH were diagnosed
according to the International Classification of Headache
Disorders (ICHD-2) criteria [23]. The control group con-
sisted of subjects who never had recurrent primary
headaches and in whom family history was negative for
primary headaches. All participants belong to the same
ethnic group and had comparable socio-economic status.
None of the subjects was genetically related to the other
subjects included in the study.
Subjects with any of the following disorders were
excluded from the study: major neurological disorders e.g.,
epilepsy, space occupying lesions, neurodegenerative dis-
orders, substance use disorder (except tobacco), chronic
daily headache (undiagnosed or mixed type), other co-
morbid headache, taking prophylactic therapy for migraine
and TTH for more than three weeks, consuming anti-
oxidants or multivitamins for more than three weeks, and
co-morbid psychiatric disorder.
Patient’s history of headache was taken in detail, fol-
lowed by the clinical examination and wherever required,
appropriate laboratory investigation to rule out secondary
headache. Parallel information was also collected from
a reliable family member regarding headaches of the
sufferer. All the information were recorded on a
semi-structured Performa.
Measurement of CCRP in plasma
Fasting venous blood (3 ml) was collected in a sterile
EDTA vacutainer, at least 3 days after the attack of
headache and the subjects were made to take rest for at
least 2 h before drawing the blood. Sample was immedi-
ately centrifuged at 2,000 rpm for 3 min and plasma was
transferred to another sterile clean vial to keep at -70C
till further use. CGRP assay was done with the help of
Human a-CGRP ELISA kit (Peninsula Labs, LLC). After
the test, absorbance was measured at 450 nm with the help
of ELISA reader. Resultant readings were plotted against
the standard curve to find out concentration of CGRP in
each sample (ng/ml).
Statistical analysis
Analysis was done with the help of SPSS V 11.0 for
Windows. Chi-square test was used to compare the non-
parametric variables. To compare the CGRP levels
between two groups, independent sample t test was used.
One-way ANOVA with post hoc Tukey, wherever
required, was applied to compare the CGRP levels among
three groups. Univariate linear regression was used to find
out the association between numerical variables.
Results
Three groups were identical with respect to average age
(27.66 years among migraineurs; TTH group 27.6 years;
control group 25.18 years). Both the headache groups had
preponderance of females as compared to control group
(82% among migraineurs; 100% in TTH group; 25% in
control group; v2 = 70.59, P \ 0.001). Thus, it shows a
skewed gender distribution, the reason for which are dis-
cussed below. BMI was not different among groups and
none of the subjects fell into the category of ‘‘obese’’
(migraine 23.4; TTH 22.7; control 23.9; P [ 0.05).
When other illness-related factors were analysed, it was
found that migraine and TTH groups did not differ with
regards to total duration of illness, duration since the illness
has become disabling and duration of individual headache
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episode. However, migraineurs had less frequent headaches
per month (10 vs. 22 episodes of TTH; P \ 0.05) but
headache took more time to reach the maximal severity
among migraineurs (1.36 vs. 0.30 h in TTH patients;
P \ 0.05). Chronic TTH was present in 56% and chronic
migraine in 14% subjects.
Plasma CGRP level was not affected by gender (t =
-1.36; P = 0.17) though it was slightly higher among
females. Similarly, CGRP level was not different among
three diagnostic groups (F = 0.78; P = 0.49) and was
minimally affected by age (R2 = 0.03, migraine; R2 =
0.25, TTH; R2 = 0.28, control group; P [ 0.05). The
CGRP level was comparable among sub-groups of
migraineurs (Table 1). Similarly, plasma CGRP concen-
tration was not different among episodic TTH and chronic
TTH groups (t = 0.32; P = 0.97) and comparison of epi-
sodic and chronic migraine groups also revealed similar
results in this study (1.14 vs. 0.94 ng/ml; P = 0.23).
Discussion
First, whether the blood was drawn from jugular vein or
ante-cubital vein was a major issue for us. Since, migraine
is primarily a cephalic neurovascular disorder, it was
expected that CGRP concentration should be higher in the
jugular blood than the peripheral blood. Previous studies
have suggested that CGRP is increased in the internal as
well as external jugular venous blood during headache
[7, 18]. Whether the concentration is also increased in the
peripheral blood is still debatable. One body of evidence
suggests that level of CGRP in the external jugular blood
and peripheral blood is significantly different on non-
headache days, but not on the headache days in patients
[18]. However, another evidence points out that neuro-
peptide concentration increases in the peripheral blood on
the headache days in patients, however, the concentration
is comparable between migraineurs and control group on
non-headache days [13]. At the same time, another study
found that CGRP concentration in external jugular blood
was comparable to the concentration in ante-cubital blood
not only during the ictal period but also during the inter-
ictal period [17]. Thus, in light of conflicting evidences, it
is difficult to discern whether CGRP concentration is dif-
ferent between the blood drawn from these two sources.
Moreover, jugular blood goes to right atrium of heart and
then to the whole body, hence, it was expected that the
CGRP would be present in blood collected from the ante-
cubital vein. In addition, the antecubital vein is more easily
accessible and sample recruitment is convenient if we
collect blood from this site instead of puncturing any of the
jugular veins. Since the EIA kit used in this study has good
sensitivity (range 0–25 ng/ml), we decided to draw the
blood sample from ante-cubital vein.
Present study shows that plasma CGRP concentration is
not elevated in migraineurs or TTH sufferers as compared
to control group during the inter-episodic period. Previous
studies regarding plasma CGRP level measured in the
inter-episodic period among migraineurs and TTH subjects
had shown contradictory results. Where on one hand,
Gallai et al. [13] and Tvedskov et al. [17] did not find
increased CGRP levels in the plasma during inter-episodic
period, on the other hand, Ashina et al. [15] suggested that
CGRP level remains elevated in migraineurs outside
headache period as compared to controls. During inter-ictal
period, the elevated CGRP was reported not only in the
blood but also in the saliva of migraineurs [6, 16]. Nitrate
induced experimental migraine attacks have shown an
increase in the plasma CGRP during headache phase and
its normalization with the spontaneous cessation of pain as
well as in those patients who responded to the triptan
therapy suggesting the causative role of CGRP in migraine
[8, 9]. In light of these evidences, the differences in the
results could be due to the differences in the subject
selection, source of blood sample (cubital vs. jugular as
discussed above), timing of blood sample collection after
the last headache and other factors that affect CGRP levels.
If samples are drawn very early in the attack, CGRP may
not be elevated as it reaches to its peak 1.5 h of onset from
migraine and normalizes by 6 h [7]. It must also be con-
sidered that CGRP is not specific to migraine and as
already mentioned, other factors, viz., obesity, intake of
fatty meals and amount of exercise may affect the CGRP
levels [21, 22]. Almost all these studies are silent regarding
these factors. Other possibility is that migraine is truly an
episodic disorder, since blood flow studies suggest normal
cerebral blood flow outside migraine episodes and CGRP
concentration in plasma falls to normal after spontaneous
as well as triptan induced termination of migraine attacks
[8, 9, 24]. Comparable concentration of CGRP in chronic
migraineurs in the present study further confirms this
notion.
Table 1 Plasma CGRP levels (ng/ml) among diagnostic sub-group of
migraineurs








MO 37 1.15 0.55 0.97 1.33 0.69 3.10
MOMA 7 1.03 0.14 0.90 1.16 0.79 1.17
MA 6 1.15 0.50 0.62 1.68 0.68 2.10
F = 0.16; P = 0.85
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Whether CGRP is involved in the pathophysiology of
TTH is still an enigma. Glyceryltrinitrate is known to
induce TTH in CTTH sufferers upon infusion [25]. This
GTN may cause increase in the CGRP levels in TTH
patients similar to migraineurs [26]. Moreover, NOS
inhibitors are known to prevent the GTN induced TTH in
these patients [27]. Still, some studies failed to find
increased CGRP levels in the plasma of the CTTH patients
upon GTN infusion [3]. Ashina et al. [18] reported that
plasma CGRP level in TTH subjects is comparable to that
of controls and is independent of headache state. Hence, it
appears that CGRP has a role in TTH and it interacts with
nitrate or nitric oxide. But, the above statement does not
necessitate that CGRP should be increased in peripheral
blood in TTH subjects during headache. A number of
observations explain why CGRP can be instrumental in
TTH despite the fact that its concentration is not increased
in peripheral blood. First, CGRP is present not only in the
peripheral endings of trigeminal nerves close to dural
vessels but also in the trigeminal nucleus itself [28–30].
Here, they are co-localized with the 5HT1D receptor, and
CGRP may be instrumental in the central sensitization [30].
Second, CGRP receptors are found in the dural vascular
smooth muscles as well as in the trigeminal ganglia. In the
trigeminal nucleus, they are found on the satellite glial
cells, where their activation induces the iNOS and conse-
quently NO release. This, in turn, initiates inflammatory
reaction in the ganglia that is responsible for central
sensitization [1]. Third, after peripheral stimulation of
the trigeminal nerve, the surrounding glia and trigeminal
ganglion cells communicate through gap junctions. This
opening of gap junction is not time bound and they either
increase in number or remain opened for a long time after
the stimulation of trigeminal nerve. Activation of any
branch of trigeminal nerves increases SB100 and p53 not
only in the cell body of respective fibres but also in the
other two branches through paracrine communication. This
can also induce sensitization. Here, it must be noted that
central sensitization may be the underlying factor in
development of chronic TTH [31]. In addition, CGRP
differentially regulates the secretion of cytokines in
trigeminal nerve which may be responsible for other
symptoms associated with headache [2, 30]. In short, these
arguments suggest that neuropeptide may be pathophysio-
logically important even when its concentration in
peripheral blood is not increased. Considering all this,
serum CGRP concentration may not be elevated in TTH no
matter if it is episodic or chronic or, possibly like migraine,
TTH could also be an episodic disorder.
Another important finding was the absence of difference
between chronic TTH and episodic TTH subjects. This
could be due to small sample size and further reduction
when the sample was divided into chronic TTH and
episodic TTH groups. Hence, type II errors could not be
excluded. In addition, whether episodic TTH shares path-
ophysiological underpinnings with chronic TTH is yet to
be discovered and literature show contradictory findings.
Mazzotta et al. [32] found lower pain perception threshold
in episodic TTH patients as compared to control group
whilst Jensen et al. [33] reported that pain perception
threshold does not differ between episodic and chronic
TTH patients. To compound the situation, reviews avail-
able on this subject favour the occurrence of central
sensitization in CTTH with peri-cranial tenderness whilst
questioning its importance during episodic TTH [30–34].
Similarly, it is yet to be investigated if CGRP secretion and
its plasma concentration are related to central sensitization.
Such a study can throw more light on this issue as well as
explain the conflicting results found in various studies.
Results of the present study suggest that CGRP concen-
tration is not elevated during inter-episodic period among
migraineurs and TTH subjects questioning the utility of
CGRP antagonists as prophylactic agents as we have pro-
posed earlier.
The strength of the present study lies in the strict
exclusion criteria. All the subjects included in this study
were not having any other illness or other confounding
factors as already discussed. Hence, the results of this
study show the findings that represent the migraine and
TTH exclusively. Second, most of the studies in the past
followed clinical criteria for diagnosis of migraine and
TTH which lead to inclusion of non-identical subjects. We
followed the ICHD-2 criteria for diagnosis of migraine and
TTH; hence, the selection bias could be excluded.
However, this study also had some methodological
limitations. First, strict inclusion criteria in this study pre-
clude from generalizing the results as subjects with such
isolated illness are not very common in the clinics. Hence,
results must be applied with caution in the general popu-
lation. Second, sample size of the study was small relative
to the prevalence of the illnesses in question owing to few
technical factors. We suggest inclusion of a larger sample
in the future studies. Third, the results of the study repre-
sent only cross-sectional examination during a specified
period of illness. In future, sequential measurement may be
made at different phases of the illness to elucidate the
underlying pathophysiology in all groups included in this
study. Fourth, the gender distribution was skewed and the
study sample had preponderance of female gender. This
could be due to two reasons: one, the migraine as well as
TTH is more prevalent in females [35] and secondly, the
illness included in the exclusion criteria is relatively less
prevalent in females. Fifth, the female hormones may also
affect the CGRP expression in dorsal root ganglia and
pregnancy may influence the plasma CGRP level [36, 37].
However, whether the normal cycle affects the CGRP
164 J Headache Pain (2009) 10:161–166
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concentration is not known. We did not take into account
this issue whilst recruitment and it could also have affected
the results of study.
In essence, this study suggests that migraine and TTH
are episodic disorders. Both may be pathophysiologically
overlapping conditions, but further studies are required to
throw more light on this issue.
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